Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04699604
PHASE3

A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma (HAS3)

Sponsor: Bridgette Jones

View on ClinicalTrials.gov

Summary

This is a randomized, double-blind, placebo-controlled, crossover study comparing asthma control post treatment in African American/Black and Caucasian/White children in both hyper and hypo responsive HILD (Histamine Lontophoresis with Laser Doppler monitoring) phenotypes with uncontrolled persistent allergic asthma using Levocetirizine (LTZ) vs placebo.

Official title: A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma

Key Details

Gender

All

Age Range

6 Years - 17 Years

Study Type

INTERVENTIONAL

Enrollment

300

Start Date

2021-04-28

Completion Date

2026-09-30

Last Updated

2026-04-08

Healthy Volunteers

No

Conditions

Interventions

DRUG

Levocetirizine Dihydrochloride

At the end of the HILD assessment participants will be randomized to Levocetirizine Dihydrochloride or placebo. Children will be randomized by an investigational pharmacist to add-on either Levocetirizine dihydrochloride/ Xyzal® (UCB, Inc.) immediate release oral solution 2.5mg/5ml (2.5mg in children 6-11 years of age; 5mg in children \>11 years per recommended doses) or placebo to their current asthma regimen.

DRUG

Placebo

Placebo

Locations (1)

Children's Mercy Hospital

Kansas City, Missouri, United States